Format
Items per page
Sort by

Send to:

Choose Destination

Selected items

Items: 20

1.

Pathophysiology of hepatitis C virus infection and related liver disease.

Pawlotsky JM.

Trends Microbiol. 2004 Feb;12(2):96-102. Review.

PMID:
15036326
2.

Telaprevir for previously untreated chronic hepatitis C virus infection.

Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S; ADVANCE Study Team.

N Engl J Med. 2011 Jun 23;364(25):2405-16. doi: 10.1056/NEJMoa1012912.

3.

Antiviral strategies in hepatitis C virus infection.

Sarrazin C, Hézode C, Zeuzem S, Pawlotsky JM.

J Hepatol. 2012;56 Suppl 1:S88-100. doi: 10.1016/S0168-8278(12)60010-5. Review.

PMID:
22300469
4.

Response-guided telaprevir combination treatment for hepatitis C virus infection.

Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, Adler M, Reesink HW, Martin M, Sankoh AJ, Adda N, Kauffman RS, George S, Wright CI, Poordad F; ILLUMINATE Study Team.

N Engl J Med. 2011 Sep 15;365(11):1014-24. doi: 10.1056/NEJMoa1014463. Erratum in: N Engl J Med. 2011 Oct 20;365(16):1551.

5.

Factors that predict response of patients with hepatitis C virus infection to boceprevir.

Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS, Poynard T, Morgan TR, Molony C, Pedicone LD, Sings HL, Burroughs MH, Sniukiene V, Boparai N, Goteti VS, Brass CA, Albrecht JK, Bacon BR; SPRINT-2 and RESPOND-2 Investigators.

Gastroenterology. 2012 Sep;143(3):608-18.e1-5. doi: 10.1053/j.gastro.2012.05.011. Epub 2012 May 21.

PMID:
22626609
6.

New therapies for chronic hepatitis C infection: a systematic review of evidence from clinical trials.

Lee LY, Tong CY, Wong T, Wilkinson M.

Int J Clin Pract. 2012 Apr;66(4):342-55. doi: 10.1111/j.1742-1241.2012.02895.x. Review.

PMID:
22420497
7.

The prevalence of hepatitis C virus infection in the United States, 1999 through 2002.

Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ.

Ann Intern Med. 2006 May 16;144(10):705-14.

PMID:
16702586
8.

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases.

Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB; American Association for Study of Liver Diseases.

Hepatology. 2011 Oct;54(4):1433-44. doi: 10.1002/hep.24641. Epub 2011 Sep 26. No abstract available.

9.

New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives.

Welsch C, Jesudian A, Zeuzem S, Jacobson I.

Gut. 2012 May;61 Suppl 1:i36-46. doi: 10.1136/gutjnl-2012-302144. Review. Erratum in: Gut. 2012 Aug;61(8):1145.

PMID:
22504918
10.

The role of humoral innate immunity in hepatitis C virus infection.

Tarr AW, Urbanowicz RA, Ball JK.

Viruses. 2012 Jan;4(1):1-27. doi: 10.3390/v4010001. Epub 2012 Jan 5. Review.

11.

Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office.

Yee HS, Chang MF, Pocha C, Lim J, Ross D, Morgan TR, Monto A; Department of Veterans Affairs Hepatitis C Resource Center Program; National Hepatitis C Program Office.

Am J Gastroenterol. 2012 May;107(5):669-89; quiz 690. doi: 10.1038/ajg.2012.48.

PMID:
22525303
12.

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J.

N Engl J Med. 2002 Sep 26;347(13):975-82.

13.

Advances in the treatment of hepatitis C virus infection.

Thomas DL.

Top Antivir Med. 2012 Apr-May;20(1):5-10.

14.

Correlation between fibroscan, liver biopsy, and clinical liver function in patients with hepatitis C virus infection after renal transplantation.

Muñoz R, Ramírez E, Fernandez I, Martin A, Romero M, Romero E, Dominguez-Gil B, Hernandez A, Morales E, Andres A, Castellano G, Morales JM.

Transplant Proc. 2009 Jul-Aug;41(6):2425-6. doi: 10.1016/j.transproceed.2009.06.103.

PMID:
19715940
15.

A genetically humanized mouse model for hepatitis C virus infection.

Dorner M, Horwitz JA, Robbins JB, Barry WT, Feng Q, Mu K, Jones CT, Schoggins JW, Catanese MT, Burton DR, Law M, Rice CM, Ploss A.

Nature. 2011 Jun 8;474(7350):208-11. doi: 10.1038/nature10168.

16.

[Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].

Hunyady B, Kovács B, Battyáni Z.

Orv Hetil. 2011 Dec 11;152(50):1997-2009. doi: 10.1556/OH.2011.29266. Review. Hungarian.

PMID:
22112373
17.

EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

European Association for the Study of the Liver.

J Hepatol. 2011 Aug;55(2):245-64. doi: 10.1016/j.jhep.2011.02.023. Epub 2011 Mar 1. No abstract available.

18.

New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets.

Ploss A, Dubuisson J.

Gut. 2012 May;61 Suppl 1:i25-35. doi: 10.1136/gutjnl-2012-302048. Review.

PMID:
22504917
19.

Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis.

Cooper CL, Druyts E, Thorlund K, Nachega JB, El Khoury AC, O'Regan C, Mills EJ.

Ther Clin Risk Manag. 2012;8:105-30. doi: 10.2147/TCRM.S29830. Epub 2012 Mar 9.

20.

AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection.

Sheth SG, Flamm SL, Gordon FD, Chopra S.

Am J Gastroenterol. 1998 Jan;93(1):44-8.

PMID:
9448172
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk